 | • レポートコード：D0GIR-01615 • 出版社/出版日：GlobalInfoResearch / 2020年9月23日 ※2024年版があります。お問い合わせください。 • レポート形態：英文、PDF、100ページ • 納品方法：Eメール • 産業分類：医療、製薬、バイオ |
| Single User | ￥515,040 (USD3,480) | ▷ お問い合わせ |
| Multi User | ￥772,560 (USD5,220) | ▷ お問い合わせ |
| Corporate User | ￥1,030,080 (USD6,960) | ▷ お問い合わせ |
• お支払方法：銀行振込（納品後、ご請求書送付）
レポート概要
| 本調査レポートでは、脊髄性筋萎縮症（SMA）治療の世界市場を広く調査・分析し、今後の市場展望をまとめております。脊髄性筋萎縮症（SMA）治療の種類別市場規模（ヌシネルセン、オナセムノゲンアベパルボベック）、用途別市場規模（タイプ1 SMA、タイプ2 SMA、その他）、地域別市場規模（北米、アメリカ、ヨーロッパ、アジア、中国、日本、東南アジア、南米、中東、アフリカなど）、市場動向、企業別販売量と市場シェアなどの情報を掲載しています。 ・市場概要 ・企業情報（販売量、市場シェア、製品概要、SWOT分析）：Biogen、Astellas Pharma、Novartis、Roche、Genzyme Corporation ・地域別グローバル市場分析 2015年-2020年 ・脊髄性筋萎縮症（SMA）治療の北米市場（アメリカ、カナダ、メキシコ） ・脊髄性筋萎縮症（SMA）治療のヨーロッパ市場（ドイツ、イギリス、フランス、ロシア、イタリア） ・脊髄性筋萎縮症（SMA）治療のアジア市場（中国、日本、韓国、インド、東南アジア、オーストラリア） ・脊髄性筋萎縮症（SMA）治療の南米市場（ブラジル、アルゼンチン） ・脊髄性筋萎縮症（SMA）治療の中東・アフリカ市場（サウジアラビア、トルコ、エジプト、南アフリカ） ・種類別分析：ヌシネルセン、オナセムノゲンアベパルボベック ・用途別分析：タイプ1 SMA、タイプ2 SMA、その他 ・地域別市場規模予測 2021年-2025年 ・調査の結果・結論 |
Market Overview
The Spinal Muscular Atrophy (SMA) Therapeutic market report provides a detailed analysis of global market size, regional and country-level market size, segmentation market growth, market share, competitive Landscape, sales analysis, impact of domestic and global market players, value chain optimization, trade regulations, recent developments, opportunities analysis, strategic market growth analysis, product launches, area marketplace expanding, and technological innovations.
The most likely (base case) scenario is that the global Spinal Muscular Atrophy (SMA) Therapeutic sales will be xx in 2020 from Spinal Muscular Atrophy (SMA) Therapeutic million in 2019, with a change xx% between 2019 and 2020. In addition, based on the latest study, it is to predict that the Covid-19 will be under control in key countries like the United States, Western Europe, East Asia, by the end of Q2 (June), and will resume normal production in Q3 and Q4, the global Spinal Muscular Atrophy (SMA) Therapeutic market size is expected to grow at xx% or more annually for the next five years.
This report also researches and evaluates the impact of Covid-19 outbreak on the Spinal Muscular Atrophy (SMA) Therapeutic industry, involving potential opportunity and challenges, drivers and risks. We present the impact assessment of Covid-19 effects on Spinal Muscular Atrophy (SMA) Therapeutic and market growth forecast based on different scenario (optimistic, pessimistic, very optimistic, most likely etc.).
Market segmentation
Spinal Muscular Atrophy (SMA) Therapeutic market is split by Type and by Application. For the period 2015-2025, the growth among segments provide accurate calculations and forecasts for sales by Type and by Application in terms of volume and value. This analysis can help you expand your business by targeting qualified niche markets.
By Type, Spinal Muscular Atrophy (SMA) Therapeutic market has been segmented into:
Nusinersen
Onasemnogen Abeparvovec
By Application, Spinal Muscular Atrophy (SMA) Therapeutic has been segmented into:
Type 1 SMA
Type 2 SMA
Other
Regions and Countries Level Analysis
Regional analysis is another highly comprehensive part of the research and analysis study of the global Spinal Muscular Atrophy (SMA) Therapeutic market presented in the report. This section sheds light on the sales growth of different regional and country-level Spinal Muscular Atrophy (SMA) Therapeutic markets. For the historical and forecast period 2015 to 2025, it provides detailed and accurate country-wise volume analysis and region-wise market size analysis of the global Spinal Muscular Atrophy (SMA) Therapeutic market.
The report offers in-depth assessment of the growth and other aspects of the Spinal Muscular Atrophy (SMA) Therapeutic market in important countries (regions), including:
North America (United States, Canada and Mexico)
Europe (Germany, France, UK, Russia and Italy)
Asia-Pacific (China, Japan, Korea, India, Southeast Asia and Australia)
South America (Brazil, Argentina, Colombia)
Middle East and Africa (Saudi Arabia, UAE, Egypt, Nigeria and South Africa)
Competitive Landscape and Spinal Muscular Atrophy (SMA) Therapeutic Market Share Analysis
Spinal Muscular Atrophy (SMA) Therapeutic competitive landscape provides details by vendors, including company overview, company total revenue (financials), market potential, global presence, Spinal Muscular Atrophy (SMA) Therapeutic sales and revenue generated, market share, price, production sites and facilities, SWOT analysis, product launch. For the period 2015-2020, this study provides the Spinal Muscular Atrophy (SMA) Therapeutic sales, revenue and market share for each player covered in this report.
The major players covered in Spinal Muscular Atrophy (SMA) Therapeutic are:
Biogen
Astellas Pharma
Novartis
Roche
Genzyme Corporation
Among other players domestic and global, Spinal Muscular Atrophy (SMA) Therapeutic market share data is available for global, North America, Europe, Asia-Pacific, Middle East & Africa and South America separately. Global Info Research analysts understand competitive strengths and provide competitive analysis for each competitor separately.
1 Spinal Muscular Atrophy (SMA) Therapeutic Market Overview
1.1 Product Overview and Scope of Spinal Muscular Atrophy (SMA) Therapeutic
1.2 Classification of Spinal Muscular Atrophy (SMA) Therapeutic by Type
1.2.1 Global Spinal Muscular Atrophy (SMA) Therapeutic Revenue by Type: 2015 VS 2019 VS 2025
1.2.2 Global Spinal Muscular Atrophy (SMA) Therapeutic Revenue Market Share by Type in 2019
1.2.3 Nusinersen
1.2.4 Onasemnogen Abeparvovec
1.3 Global Spinal Muscular Atrophy (SMA) Therapeutic Market by Application
1.3.1 Overview: Global Spinal Muscular Atrophy (SMA) Therapeutic Revenue by Application: 2015 VS 2019 VS 2025
1.3.2 Type 1 SMA
1.3.3 Type 2 SMA
1.3.4 Other
1.4 Global Spinal Muscular Atrophy (SMA) Therapeutic Market by Regions
1.4.1 Global Spinal Muscular Atrophy (SMA) Therapeutic Market Size by Regions: 2015 VS 2019 VS 2025
1.4.2 Global Market Size of Spinal Muscular Atrophy (SMA) Therapeutic (2015-2025)
1.4.3 North America (USA, Canada and Mexico) Spinal Muscular Atrophy (SMA) Therapeutic Status and Prospect (2015-2025)
1.4.4 Europe (Germany, France, UK, Russia and Italy) Spinal Muscular Atrophy (SMA) Therapeutic Status and Prospect (2015-2025)
1.4.5 Asia-Pacific (China, Japan, Korea, India and Southeast Asia) Spinal Muscular Atrophy (SMA) Therapeutic Status and Prospect (2015-2025)
1.4.6 South America (Brazil, Argentina, Colombia) Spinal Muscular Atrophy (SMA) Therapeutic Status and Prospect (2015-2025)
1.4.7 Middle East & Africa (Saudi Arabia, UAE, Egypt, Nigeria and South Africa) Spinal Muscular Atrophy (SMA) Therapeutic Status and Prospect (2015-2025)
1.5 COVID-19 Outbreak: Spinal Muscular Atrophy (SMA) Therapeutic Industry Impact
1.5.1 COVID-19 Potential Implications for the Spinal Muscular Atrophy (SMA) Therapeutic
1.5.1.1 Scenario One: Very Optimistic: COVID-19 has No Influence on Spinal Muscular Atrophy (SMA) Therapeutic
1.5.1.2 Scenario Two: Optimistic: COVID-19 Will Be Under Control by the End of April
1.5.1.3 Scenario Three: Gloomy: COVID-19 Will Be Under Control Between Q3 and Q4
1.5.1.4 Scenario Four: Most Likely: COVID-19 Will Be Under Control by the End of Q2
1.5.2 Opportunity Analysis in Covid-19 Crisis
1.5.3 Market Risk and Restraints
1.5.4 Market Driving Force
2 Company Profiles
2.1 Biogen
2.1.1 Biogen Details
2.1.2 Biogen Major Business and Total Revenue (Financial Highlights) Analysis
2.1.3 Biogen SWOT Analysis
2.1.4 Biogen Product and Services
2.1.5 Biogen Spinal Muscular Atrophy (SMA) Therapeutic Revenue, Gross Margin and Market Share (2018-2019)
2.2 Astellas Pharma
2.2.1 Astellas Pharma Details
2.2.2 Astellas Pharma Major Business and Total Revenue (Financial Highlights) Analysis
2.2.3 Astellas Pharma SWOT Analysis
2.2.4 Astellas Pharma Product and Services
2.2.5 Astellas Pharma Spinal Muscular Atrophy (SMA) Therapeutic Revenue, Gross Margin and Market Share (2018-2019)
2.3 Novartis
2.3.1 Novartis Details
2.3.2 Novartis Major Business and Total Revenue (Financial Highlights) Analysis
2.3.3 Novartis SWOT Analysis
2.3.4 Novartis Product and Services
2.3.5 Novartis Spinal Muscular Atrophy (SMA) Therapeutic Revenue, Gross Margin and Market Share (2018-2019)
2.4 Roche
2.4.1 Roche Details
2.4.2 Roche Major Business and Total Revenue (Financial Highlights) Analysis
2.4.3 Roche SWOT Analysis
2.4.4 Roche Product and Services
2.4.5 Roche Spinal Muscular Atrophy (SMA) Therapeutic Revenue, Gross Margin and Market Share (2018-2019)
2.5 Genzyme Corporation
2.5.1 Genzyme Corporation Details
2.5.2 Genzyme Corporation Major Business and Total Revenue (Financial Highlights) Analysis
2.5.3 Genzyme Corporation SWOT Analysis
2.5.4 Genzyme Corporation Product and Services
2.5.5 Genzyme Corporation Spinal Muscular Atrophy (SMA) Therapeutic Revenue, Gross Margin and Market Share (2018-2019)
3 Market Competition, by Players
3.1 Global Spinal Muscular Atrophy (SMA) Therapeutic Revenue and Share by Players (2015-2020)
3.2 Market Concentration Rate
3.2.1 Top 5 Spinal Muscular Atrophy (SMA) Therapeutic Players Market Share
3.2.2 Top 10 Spinal Muscular Atrophy (SMA) Therapeutic Players Market Share
3.3 Market Competition Trend
4 Market Size by Regions
4.1 Global Spinal Muscular Atrophy (SMA) Therapeutic Revenue and Market Share by Regions
4.2 North America Spinal Muscular Atrophy (SMA) Therapeutic Revenue and Growth Rate (2015-2020)
4.3 Europe Spinal Muscular Atrophy (SMA) Therapeutic Revenue and Growth Rate (2015-2020)
4.4 Asia-Pacific Spinal Muscular Atrophy (SMA) Therapeutic Revenue and Growth Rate (2015-2020)
4.5 South America Spinal Muscular Atrophy (SMA) Therapeutic Revenue and Growth Rate (2015-2020)
4.6 Middle East & Africa Spinal Muscular Atrophy (SMA) Therapeutic Revenue and Growth Rate (2015-2020)
5 North America Spinal Muscular Atrophy (SMA) Therapeutic Revenue by Countries
5.1 North America Spinal Muscular Atrophy (SMA) Therapeutic Revenue by Countries (2015-2020)
5.2 USA Spinal Muscular Atrophy (SMA) Therapeutic Revenue and Growth Rate (2015-2020)
5.3 Canada Spinal Muscular Atrophy (SMA) Therapeutic Revenue and Growth Rate (2015-2020)
5.4 Mexico Spinal Muscular Atrophy (SMA) Therapeutic Revenue and Growth Rate (2015-2020)
6 Europe Spinal Muscular Atrophy (SMA) Therapeutic Revenue by Countries
6.1 Europe Spinal Muscular Atrophy (SMA) Therapeutic Revenue by Countries (2015-2020)
6.2 Germany Spinal Muscular Atrophy (SMA) Therapeutic Revenue and Growth Rate (2015-2020)
6.3 UK Spinal Muscular Atrophy (SMA) Therapeutic Revenue and Growth Rate (2015-2020)
6.4 France Spinal Muscular Atrophy (SMA) Therapeutic Revenue and Growth Rate (2015-2020)
6.5 Russia Spinal Muscular Atrophy (SMA) Therapeutic Revenue and Growth Rate (2015-2020)
6.6 Italy Spinal Muscular Atrophy (SMA) Therapeutic Revenue and Growth Rate (2015-2020)
7 Asia-Pacific Spinal Muscular Atrophy (SMA) Therapeutic Revenue by Countries
7.1 Asia-Pacific Spinal Muscular Atrophy (SMA) Therapeutic Revenue by Countries (2015-2020)
7.2 China Spinal Muscular Atrophy (SMA) Therapeutic Revenue and Growth Rate (2015-2020)
7.3 Japan Spinal Muscular Atrophy (SMA) Therapeutic Revenue and Growth Rate (2015-2020)
7.4 Korea Spinal Muscular Atrophy (SMA) Therapeutic Revenue and Growth Rate (2015-2020)
7.5 India Spinal Muscular Atrophy (SMA) Therapeutic Revenue and Growth Rate (2015-2020)
7.6 Southeast Asia Spinal Muscular Atrophy (SMA) Therapeutic Revenue and Growth Rate (2015-2020)
8 South America Spinal Muscular Atrophy (SMA) Therapeutic Revenue by Countries
8.1 South America Spinal Muscular Atrophy (SMA) Therapeutic Revenue by Countries (2015-2020)
8.2 Brazil Spinal Muscular Atrophy (SMA) Therapeutic Revenue and Growth Rate (2015-2020)
8.3 Argentina Spinal Muscular Atrophy (SMA) Therapeutic Revenue and Growth Rate (2015-2020)
9 Middle East & Africa Revenue Spinal Muscular Atrophy (SMA) Therapeutic by Countries
9.1 Middle East & Africa Spinal Muscular Atrophy (SMA) Therapeutic Revenue by Countries (2015-2020)
9.2 Saudi Arabia Spinal Muscular Atrophy (SMA) Therapeutic Revenue and Growth Rate (2015-2020)
9.3 UAE Spinal Muscular Atrophy (SMA) Therapeutic Revenue and Growth Rate (2015-2020)
9.4 Egypt Spinal Muscular Atrophy (SMA) Therapeutic Revenue and Growth Rate (2015-2020)
9.5 South Africa Spinal Muscular Atrophy (SMA) Therapeutic Revenue and Growth Rate (2015-2020)
10 Market Size Segment by Type
10.1 Global Spinal Muscular Atrophy (SMA) Therapeutic Revenue and Market Share by Type (2015-2020)
10.2 Global Spinal Muscular Atrophy (SMA) Therapeutic Market Forecast by Type (2019-2024)
10.3 Nusinersen Revenue Growth Rate (2015-2025)
10.4 Onasemnogen Abeparvovec Revenue Growth Rate (2015-2025)
11 Global Spinal Muscular Atrophy (SMA) Therapeutic Market Segment by Application
11.1 Global Spinal Muscular Atrophy (SMA) Therapeutic Revenue Market Share by Application (2015-2020)
11.2 Spinal Muscular Atrophy (SMA) Therapeutic Market Forecast by Application (2019-2024)
11.3 Type 1 SMA Revenue Growth (2015-2020)
11.4 Type 2 SMA Revenue Growth (2015-2020)
11.5 Other Revenue Growth (2015-2020)
12 Global Spinal Muscular Atrophy (SMA) Therapeutic Market Size Forecast (2021-2025)
12.1 Global Spinal Muscular Atrophy (SMA) Therapeutic Market Size Forecast (2021-2025)
12.2 Global Spinal Muscular Atrophy (SMA) Therapeutic Market Forecast by Regions (2021-2025)
12.3 North America Spinal Muscular Atrophy (SMA) Therapeutic Revenue Market Forecast (2021-2025)
12.4 Europe Spinal Muscular Atrophy (SMA) Therapeutic Revenue Market Forecast (2021-2025)
12.5 Asia-Pacific Spinal Muscular Atrophy (SMA) Therapeutic Revenue Market Forecast (2021-2025)
12.6 South America Spinal Muscular Atrophy (SMA) Therapeutic Revenue Market Forecast (2021-2025)
12.7 Middle East & Africa Spinal Muscular Atrophy (SMA) Therapeutic Revenue Market Forecast (2021-2025)
13 Research Findings and Conclusion
14 Appendix
14.1 Methodology
14.2 Data Source
14.3 Disclaimer
14.4 About US
Table 1. Global Spinal Muscular Atrophy (SMA) Therapeutic Revenue (USD Million) by Type: 2015 VS 2019 VS 2025
Table 2. Breakdown of Spinal Muscular Atrophy (SMA) Therapeutic by Company Type (Tier 1, Tier 2 and Tier 3)
Table 3. Global Spinal Muscular Atrophy (SMA) Therapeutic Revenue (USD Million) by Application: 2015 VS 2019 VS 2025
Table 4. Global Market Spinal Muscular Atrophy (SMA) Therapeutic Revenue (Million USD) Comparison by Regions 2015-2025
Table 5. Global Spinal Muscular Atrophy (SMA) Therapeutic Market Size and Growth Estimation in Various Scenarios in 2020
Table 6. Biogen Corporate Information, Location and Competitors
Table 7. Biogen Spinal Muscular Atrophy (SMA) Therapeutic Major Business
Table 8. Biogen Spinal Muscular Atrophy (SMA) Therapeutic Total Revenue (USD Million) (2017-2018)
Table 9. Biogen SWOT Analysis
Table 10. Biogen Spinal Muscular Atrophy (SMA) Therapeutic Product and Solutions
Table 11. Biogen Spinal Muscular Atrophy (SMA) Therapeutic Revenue (USD Million), Gross Margin and Market Share (2018-2019)
Table 12. Astellas Pharma Corporate Information, Location and Competitors
Table 13. Astellas Pharma Spinal Muscular Atrophy (SMA) Therapeutic Major Business
Table 14. Astellas Pharma Spinal Muscular Atrophy (SMA) Therapeutic Total Revenue (USD Million) (2018-2019)
Table 15. Astellas Pharma SWOT Analysis
Table 16. Astellas Pharma Spinal Muscular Atrophy (SMA) Therapeutic Product and Solutions
Table 17. Astellas Pharma Spinal Muscular Atrophy (SMA) Therapeutic Revenue (USD Million), Gross Margin and Market Share (2018-2019)
Table 18. Novartis Corporate Information, Location and Competitors
Table 19. Novartis Spinal Muscular Atrophy (SMA) Therapeutic Major Business
Table 20. Novartis Spinal Muscular Atrophy (SMA) Therapeutic Total Revenue (USD Million) (2017-2018)
Table 21. Novartis SWOT Analysis
Table 22. Novartis Spinal Muscular Atrophy (SMA) Therapeutic Product and Solutions
Table 23. Novartis Spinal Muscular Atrophy (SMA) Therapeutic Revenue (USD Million), Gross Margin and Market Share (2018-2019)
Table 24. Roche Corporate Information, Location and Competitors
Table 25. Roche Spinal Muscular Atrophy (SMA) Therapeutic Major Business
Table 26. Roche Spinal Muscular Atrophy (SMA) Therapeutic Total Revenue (USD Million) (2017-2018)
Table 27. Roche SWOT Analysis
Table 28. Roche Spinal Muscular Atrophy (SMA) Therapeutic Product and Solutions
Table 29. Roche Spinal Muscular Atrophy (SMA) Therapeutic Revenue (USD Million), Gross Margin and Market Share (2018-2019)
Table 30. Genzyme Corporation Corporate Information, Location and Competitors
Table 31. Genzyme Corporation Spinal Muscular Atrophy (SMA) Therapeutic Major Business
Table 32. Genzyme Corporation Spinal Muscular Atrophy (SMA) Therapeutic Total Revenue (USD Million) (2017-2018)
Table 33. Genzyme Corporation SWOT Analysis
Table 34. Genzyme Corporation Spinal Muscular Atrophy (SMA) Therapeutic Product and Solutions
Table 35. Genzyme Corporation Spinal Muscular Atrophy (SMA) Therapeutic Revenue (USD Million), Gross Margin and Market Share (2018-2019)
Table 36. Global Spinal Muscular Atrophy (SMA) Therapeutic Revenue (Million USD) by Players (2015-2020)
Table 37. Global Spinal Muscular Atrophy (SMA) Therapeutic Revenue Share by Players (2015-2020)
Table 38. Global Spinal Muscular Atrophy (SMA) Therapeutic Revenue (Million USD) by Regions (2015-2020)
Table 39. Global Spinal Muscular Atrophy (SMA) Therapeutic Revenue Market Share by Regions (2015-2020)
Table 40. North America Spinal Muscular Atrophy (SMA) Therapeutic Revenue by Countries (2015-2020)
Table 41. North America Spinal Muscular Atrophy (SMA) Therapeutic Revenue Market Share by Countries (2015-2020)
Table 42. Europe Spinal Muscular Atrophy (SMA) Therapeutic Revenue (Million USD) by Countries (2015-2020)
Table 43. Asia-Pacific Spinal Muscular Atrophy (SMA) Therapeutic Revenue (Million USD) by Countries (2015-2020)
Table 44. South America Spinal Muscular Atrophy (SMA) Therapeutic Revenue by Countries (2015-2020)
Table 45. South America Spinal Muscular Atrophy (SMA) Therapeutic Revenue Market Share by Countries (2015-2020)
Table 46. Middle East and Africa Spinal Muscular Atrophy (SMA) Therapeutic Revenue (Million USD) by Countries (2015-2020)
Table 47. Middle East and Africa Spinal Muscular Atrophy (SMA) Therapeutic Revenue Market Share by Countries (2015-2020)
Table 48. Global Spinal Muscular Atrophy (SMA) Therapeutic Revenue (Million USD) by Type (2015-2020)
Table 49. Global Spinal Muscular Atrophy (SMA) Therapeutic Revenue Share by Type (2015-2020)
Table 50. Global Spinal Muscular Atrophy (SMA) Therapeutic Revenue Forecast by Type (2021-2025)
Table 51. Global Spinal Muscular Atrophy (SMA) Therapeutic Revenue by Application (2015-2020)
Table 52. Global Spinal Muscular Atrophy (SMA) Therapeutic Revenue Share by Application (2015-2020)
Table 53. Global Spinal Muscular Atrophy (SMA) Therapeutic Revenue Forecast by Application (2021-2025)
Table 54. Global Spinal Muscular Atrophy (SMA) Therapeutic Revenue (Million USD) Forecast by Regions (2021-2025)
List of Figures
Figure 1. Spinal Muscular Atrophy (SMA) Therapeutic Picture
Figure 2. Global Spinal Muscular Atrophy (SMA) Therapeutic Revenue Market Share by Type in 2019
Figure 3. Nusinersen Picture
Figure 4. Onasemnogen Abeparvovec Picture
Figure 5. Spinal Muscular Atrophy (SMA) Therapeutic Revenue Market Share by Application in 2019
Figure 6. Type 1 SMA Picture
Figure 7. Type 2 SMA Picture
Figure 8. Other Picture
Figure 9. Global Spinal Muscular Atrophy (SMA) Therapeutic Revenue (USD Million) and Growth Rate (2015-2025)
Figure 10. North America Spinal Muscular Atrophy (SMA) Therapeutic Revenue (Million USD) and Growth Rate (2015-2025)
Figure 11. Europe Spinal Muscular Atrophy (SMA) Therapeutic Revenue (Million USD) and Growth Rate (2015-2025)
Figure 12. Asia-Pacific Spinal Muscular Atrophy (SMA) Therapeutic Revenue (Million USD) and Growth Rate (2015-2025)
Figure 13. South America Spinal Muscular Atrophy (SMA) Therapeutic Revenue (Million USD) and Growth Rate (2015-2025)
Figure 14. Middle East and Africa Spinal Muscular Atrophy (SMA) Therapeutic Revenue (Million USD) and Growth Rate (2015-2025)
Figure 15. Global Spinal Muscular Atrophy (SMA) Therapeutic Revenue (Million USD) and Growth Rate (2015-2025)
Figure 16. Global Spinal Muscular Atrophy (SMA) Therapeutic Revenue Share by Players in 2019
Figure 17. Global Top 5 Players Spinal Muscular Atrophy (SMA) Therapeutic Revenue Market Share in 2019
Figure 18. Global Top 10 Players Spinal Muscular Atrophy (SMA) Therapeutic Revenue Market Share in 2019
Figure 19. Key Players Market Share Trend
Figure 20. Global Spinal Muscular Atrophy (SMA) Therapeutic Revenue (Million USD) and Growth Rate (%) (2015-2020)
Figure 21. Global Spinal Muscular Atrophy (SMA) Therapeutic Revenue Market Share by Regions (2015-2020)
Figure 22. Global Spinal Muscular Atrophy (SMA) Therapeutic Revenue Market Share by Regions in 2018
Figure 23. North America Spinal Muscular Atrophy (SMA) Therapeutic Revenue and Growth Rate (2015-2020)
Figure 24. Europe Spinal Muscular Atrophy (SMA) Therapeutic Revenue and Growth Rate (2015-2020)
Figure 25. Asia-Pacific Spinal Muscular Atrophy (SMA) Therapeutic Revenue and Growth Rate (2015-2020)
Figure 26. South America Spinal Muscular Atrophy (SMA) Therapeutic Revenue and Growth Rate (2015-2020)
Figure 27. Middle East and Africa Spinal Muscular Atrophy (SMA) Therapeutic Revenue and Growth Rate (2015-2020)
Figure 28. North America Spinal Muscular Atrophy (SMA) Therapeutic Revenue Market Share by Countries (2015-2020)
Figure 29. North America Spinal Muscular Atrophy (SMA) Therapeutic Revenue Market Share by Countries in 2019
Figure 30. USA Spinal Muscular Atrophy (SMA) Therapeutic Revenue and Growth Rate (2015-2020)
Figure 31. Canada Spinal Muscular Atrophy (SMA) Therapeutic Revenue and Growth Rate (2015-2020)
Figure 32. Mexico Spinal Muscular Atrophy (SMA) Therapeutic Revenue and Growth Rate (2015-2020)
Figure 33. Europe Spinal Muscular Atrophy (SMA) Therapeutic Revenue Market Share by Countries (2015-2020)
Figure 34. Europe Spinal Muscular Atrophy (SMA) Therapeutic Revenue Market Share by Countries in 2019
Figure 35. Germany Spinal Muscular Atrophy (SMA) Therapeutic Revenue and Growth Rate (2015-2020)
Figure 36. UK Spinal Muscular Atrophy (SMA) Therapeutic Revenue and Growth Rate (2015-2020)
Figure 37. France Spinal Muscular Atrophy (SMA) Therapeutic Revenue and Growth Rate (2015-2020)
Figure 38. Russia Spinal Muscular Atrophy (SMA) Therapeutic Revenue and Growth Rate (2015-2020)
Figure 39. Italy Spinal Muscular Atrophy (SMA) Therapeutic Revenue and Growth Rate (2015-2020)
Figure 40. Asia-Pacific Spinal Muscular Atrophy (SMA) Therapeutic Revenue Market Share by Countries (2015-2020)
Figure 41. Asia-Pacific Spinal Muscular Atrophy (SMA) Therapeutic Revenue Market Share by Countries in 2019
Figure 42. China Spinal Muscular Atrophy (SMA) Therapeutic Revenue and Growth Rate (2015-2020)
Figure 43. Japan Spinal Muscular Atrophy (SMA) Therapeutic Revenue and Growth Rate (2015-2020)
Figure 44. Korea Spinal Muscular Atrophy (SMA) Therapeutic Revenue and Growth Rate (2015-2020)
Figure 45. India Spinal Muscular Atrophy (SMA) Therapeutic Revenue and Growth Rate (2015-2020)
Figure 46. Southeast Asia Spinal Muscular Atrophy (SMA) Therapeutic Revenue and Growth Rate (2015-2020)
Figure 47. South America Spinal Muscular Atrophy (SMA) Therapeutic Revenue Market Share by Countries (2015-2020)
Figure 48. South America Spinal Muscular Atrophy (SMA) Therapeutic Revenue Market Share by Countries in 2019
Figure 49. Brazil Spinal Muscular Atrophy (SMA) Therapeutic Revenue and Growth Rate (2015-2020)
Figure 50. Argentina Spinal Muscular Atrophy (SMA) Therapeutic Revenue and Growth Rate (2015-2020)
Figure 51. Middle East and Africa Spinal Muscular Atrophy (SMA) Therapeutic Revenue Market Share by Countries (2015-2020)
Figure 52. Middle East and Africa Spinal Muscular Atrophy (SMA) Therapeutic Revenue Market Share by Countries in 2019
Figure 53. Saudi Arabia Spinal Muscular Atrophy (SMA) Therapeutic Revenue and Growth Rate (2015-2020)
Figure 54. UAE Spinal Muscular Atrophy (SMA) Therapeutic Revenue and Growth Rate (2015-2020)
Figure 55. Egypt Spinal Muscular Atrophy (SMA) Therapeutic Revenue and Growth Rate (2015-2020)
Figure 56. South Africa Spinal Muscular Atrophy (SMA) Therapeutic Revenue and Growth Rate (2015-2020)
Figure 57. Global Spinal Muscular Atrophy (SMA) Therapeutic Revenue Share by Type (2015-2020)
Figure 58. Global Spinal Muscular Atrophy (SMA) Therapeutic Revenue Share by Type in 2019
Figure 59. Global Spinal Muscular Atrophy (SMA) Therapeutic Market Share Forecast by Type (2021-2025)
Figure 60. Global Nusinersen Revenue Growth Rate (2015-2020)
Figure 61. Global Onasemnogen Abeparvovec Revenue Growth Rate (2015-2020)
Figure 62. Global Spinal Muscular Atrophy (SMA) Therapeutic Revenue Share by Application (2015-2020)
Figure 63. Global Spinal Muscular Atrophy (SMA) Therapeutic Revenue Share by Application in 2019
Figure 64. Global Spinal Muscular Atrophy (SMA) Therapeutic Market Share Forecast by Application (2021-2025)
Figure 65. Global Type 1 SMA Revenue Growth Rate (2015-2020)
Figure 66. Global Type 2 SMA Revenue Growth Rate (2015-2020)
Figure 67. Global Other Revenue Growth Rate (2015-2020)
Figure 68. Global Spinal Muscular Atrophy (SMA) Therapeutic Revenue (Million USD) and Growth Rate Forecast (2021-2025)
Figure 69. Global Spinal Muscular Atrophy (SMA) Therapeutic Revenue (Million USD) Forecast by Regions (2021-2025)
Figure 70. Global Spinal Muscular Atrophy (SMA) Therapeutic Revenue Market Share Forecast by Regions (2021-2025)
Figure 71. North America Spinal Muscular Atrophy (SMA) Therapeutic Revenue Market Forecast (2021-2025)
Figure 72. Europe Spinal Muscular Atrophy (SMA) Therapeutic Revenue Market Forecast (2021-2025)
Figure 73. Asia-Pacific Spinal Muscular Atrophy (SMA) Therapeutic Revenue Market Forecast (2021-2025)
Figure 74. South America Spinal Muscular Atrophy (SMA) Therapeutic Revenue Market Forecast (2021-2025)
Figure 75. Middle East and Africa Spinal Muscular Atrophy (SMA) Therapeutic Revenue Market Forecast (2021-2025)
Figure 76. Sales Channel: Direct Channel vs Indirect Channel
デュシェンヌ型筋ジストロフィー治療の世界市場2020年：企業別、地域別、種類・用途別 Market Overview The global Duchenne Muscular Dystrophy Therapeutics market size is expected to gain market growth in the forecast period of 2020 to 2025, with a CAGR of 27.7% in the forecast period of 2020 to 2025 and will expected to reach USD 2629.3 million by 2025, from USD 989.7 million in 2019.…- 脊髄刺激（SCS）システムの世界市場2020年：メーカー別、地域別、種類・用途別 Market Overview The Spinal Cord Stimulation (SCS) Systems market report provides a detailed analysis of global market size, regional and country-level market size, segmentation market growth, market share, competitive Landscape, sales analysis, impact of domestic and global market players, value cha…
- 脊髄刺激装置（SCS）デバイスの世界市場2020年：メーカー別、地域別、種類・用途別 Market Overview The Spinal Cord Stimulator (SCS) Device market report provides a detailed analysis of global market size, regional and country-level market size, segmentation market growth, market share, competitive Landscape, sales analysis, impact of domestic and global market players, value chain…
- 脊椎手術装置の世界市場2020年：メーカー別、地域別、種類・用途別 Market Overview The global Spinal Surgery Devices market size is expected to gain market growth in the forecast period of 2020 to 2025, with a CAGR of xx% in the forecast period of 2020 to 2025 and will expected to reach USD xx million by 2025, from USD xx million in 2019. The Spinal Surgery Devices…
- 脊椎牽引の世界市場2020年：メーカー別、地域別、種類・用途別 Market Overview The global Spinal Traction market size is expected to gain market growth in the forecast period of 2020 to 2025, with a CAGR of 4.2% in the forecast period of 2020 to 2025 and will expected to reach USD 5142.8 million by 2025, from USD 4366.1 million in 2019. The Spinal Traction mark…